Lucius Lenacapavir (Lenacapavir) – Buy online
Lucius Lenacapavir (Lenacapavir) – Buy online

Lucius Lenacapavir (Lenacapavir) – Buy online

USD 373.33

Sold 3,000+
Special Offer

Offline Hong Kong pharmacy with 100% genuine product guarantee

Key Highlights

Lenacapavir was first approved in the United States in 2022 for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

Service Promise

Direct from JapanLicensed PharmacyPharmacist CheckedEditable in Admin

Specifications

Specification
300mg*5 tablets
Manufacturer
Lucius Pharmaceuticals
Shipping
Hong Kong

10000 in stock

Category: Tag: Brand:

Product Info

English Name
Lenacapavir
Generic Name
Lenacapavir

Specifications

Specification
300mg*5 tablets
Manufacturer
Lucius Pharmaceuticals
Shipping
Hong Kong

Full Details

Pharmacology

12.1 How It Works SUNLENCA HIV-1 [ (12.4)] 12.2 - CAPELLA ， HIV-1 ， 1 2 600 mg， 8 300 mg ， SUNLENCA 15 ， 6 927 mg lenacapavir ， 1 14 HIV-1 RNA ， 26 HIV-1 RNA 50 /mL lenacapavir 9 ， ，

Dosage

2.1 SUNLENCA ， 6 ， SUNLENCA ， ， [ Precautions(5.2) (12.4)] 2.2 SUNLENCA 1 2 ， 6

Precautions

5.1 ， (PCP) ， - ， ， 5.2 SUNLENCA lenacap

Contraindications

lenacapavir ， SUNLENCA SUNLENCA ， SUNLENCA CYP3A [ (7.1)]

Drug Interactions

7.1 SUNLENCA P-gp UGT1A1 CYP3A CYP3A CYP3A [ (12.3)]， SUNLENCA SUNLENCA CYP3A [ (4)] SUNLENCA CYP3A

Adverse Reactions

[ Precautions(5.1)] [ Precautions(5.3)] 6.1 ， ， SUNLENCA II/III (CAPELLA N=72) SUNLENCA HIV ， 52 71 [ ]

Storage

300 SUNLENCA ， “GSI”， “62L” SUNLENCA ， SUNLENCA 4 NDC 61958-3001-3 ，

Indications

Used with other antiretroviral medicines in adults with multidrug-resistant HIV-1 whose current regimen has failed because of resistance, intolerance, or safety concerns.

Package Insert

Ingredients

11 YEZTUGO YEZTUGO ， (4- -7-(2-((S)-1-(2-((3bS,4aR)-5,5- -3-( )-3b,4,4a,5- -1H- [3,4] [1,2-c] -1- ) )-2-(3,5- ) )-6-(3- -3-( ) -1- -1- ) -3- )-1-(2,2,2- )-1H- -3- )( ) C₃₉H₃₁ClF₁₀N₇NaO₅S₂， 990.3， ， YEZTUGO 300

Appearance

3 300 463.5 /1.5 309 / (3) YEZTUGO 300 306.8 ， “GSI”， “62L” YEZTUGO 463.5 /1.5 309 / 473.1 /1.5

Dosage

2.1 SUNLENCA ， 6 ， SUNLENCA ， ， [ Precautions(5.2) (12.4)] 2.2 SUNLENCA 1 2 ， 6

Adverse Reactions

[ Precautions(5.1)] [ Precautions(5.3)] 6.1 ， ， SUNLENCA II/III (CAPELLA N=72) SUNLENCA HIV ， 52 71 [ ]

Contraindications

lenacapavir ， SUNLENCA SUNLENCA ， SUNLENCA CYP3A [ (7.1)]

Precautions

5.1 ， (PCP) ， - ， ， 5.2 SUNLENCA lenacap

Use in Pregnancy and Lactation

8.1 ， YEZTUGO (APR) 1-800-258-4263 1 ， ， YEZTUGO ， YEZTUGO ，

Drug Interactions

7.1 SUNLENCA P-gp UGT1A1 CYP3A CYP3A CYP3A [ (12.3)]， SUNLENCA SUNLENCA CYP3A [ (4)] SUNLENCA CYP3A

Overdose

10. YEZTUGO ， YEZTUGO ， lenacapavir ，

Clinical Pharmacology

12 12.1 How It Works YEZTUGO HIV-1 [ (12.4)] 12.2 lenacapavir YEZTUGO 16 ，YEZTUGO QTcF 12.3 lenacapavir (PK) 8 YEZTUGO ， 9 YEZTUGO

Pharmacology and Toxicology

13 13.1 6 rasH2 ， ， 13 ， 300 mg/kg/ ，Lenacapavir 104 ，Lenacapavir 0 102 309 927 mg/kg， 13 927 mg/kg ， ， AUC ， RHD 44

Clinical Studies

14 PURPOSE 1 PURPOSE 2 YEZTUGO HIV-1 PURPOSE 1 16 25 ， HIV-1 ， HIV-1 HIV-1 2:2:1 YEZTUGO N=2134 DESCOVY N=2136 TRUVADA N=1068 2 16 ， HIV-1 ， HIV-1

Storage

300 SUNLENCA ， “GSI”， “62L” SUNLENCA ， SUNLENCA 4 NDC 61958-3001-3 ，

Product Reviews (12)

Filter: All Reviews
4.8★★★★★
12 customer reviews10 verified purchases
+o***e· 3 weeks ago
★★★★
+t***3· 1 months ago
Verified Purchase
★★★★★

Description

Pharmacology

12.1 How It Works SUNLENCA HIV-1 [ (12.4)] 12.2 - CAPELLA ， HIV-1 ， 1 2 600 mg， 8 300 mg ， SUNLENCA 15 ， 6 927 mg lenacapavir ， 1 14 HIV-1 RNA ， 26 HIV-1 RNA 50 /mL lenacapavir 9 ， ，

Dosage

2.1 SUNLENCA ， 6 ， SUNLENCA ， ， [ Precautions(5.2) (12.4)] 2.2 SUNLENCA 1 2 ， 6

Precautions

5.1 ， (PCP) ， - ， ， 5.2 SUNLENCA lenacap

Contraindications

lenacapavir ， SUNLENCA SUNLENCA ， SUNLENCA CYP3A [ (7.1)]

Drug Interactions

7.1 SUNLENCA P-gp UGT1A1 CYP3A CYP3A CYP3A [ (12.3)]， SUNLENCA SUNLENCA CYP3A [ (4)] SUNLENCA CYP3A

Adverse Reactions

[ Precautions(5.1)] [ Precautions(5.3)] 6.1 ， ， SUNLENCA II/III (CAPELLA N=72) SUNLENCA HIV ， 52 71 [ ]

Storage

300 SUNLENCA ， “GSI”， “62L” SUNLENCA ， SUNLENCA 4 NDC 61958-3001-3 ，

Indications

Used with other antiretroviral medicines in adults with multidrug-resistant HIV-1 whose current regimen has failed because of resistance, intolerance, or safety concerns.